Answers are grounded in this paper and cite their sources.
Patients with cancer and coexisting diabetes face challenges in wound healing, particularly after cancer surgery and anticancer treatments. Impaired re-epithelialization and keratinocyte migration may delay wound closure, affecting postoperative recovery and subsequent cancer care. Although CXCL12 is involved in tissue repair, its regulatory role under hyperglycaemic conditions remains unclear. This study investigated whether the p65/CXCL12 axis regulates keratinocyte migration and an epithelial–mesenchymal transition (EMT)-like phenotype through TGF-β/SMAD signalling. Public transcriptomic datasets and human diabetic wound specimens were analysed to assess CXCL12 expression. High-glucose-treated HaCaT cells underwent CXCL12 overexpression or siRNA knockdown, with BAY 11–7082 and LY2157299 used to interfere with p65‐ and TGF-β-related signalling, respectively. Cell migration and molecular changes were evaluated using scratch and Transwell assays, qRT-PCR, immunoblotting and immunofluorescence. CXCL12/CXCR4 signalling was further examined in diabetic mouse wounds using AMD3100. CXCL12 expression, keratinocyte migration and EMT-like changes were reduced under diabetic conditions. CXCL12 overexpression enhanced migration and EMT-associated changes, whereas knockdown produced opposite effects. Inhibition of p65-related signalling reduced CXCL12 expression and migration, while CXCL12 restoration partially reversed these effects. TGF-β inhibition attenuated CXCL12-induced migration and EMT-like responses. In diabetic mice, CXCR4 antagonism reduced TGF-β/SMAD activation and delayed wound closure. These findings suggest that p65-related signalling may regulate CXCL12 expression, which subsequently engages TGF-β/SMAD signalling to support keratinocyte migration and EMT-like plasticity during diabetic wound repair. This regulatory axis may represent a potential therapeutic target for difficult-to-heal wounds in patients with cancer and coexisting diabetes. Further validation in cancer-specific diabetic wound models is warranted.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: